ES2293977T3 - Peptidos antivirales farmacologicamente activos y metodo para su uso. - Google Patents
Peptidos antivirales farmacologicamente activos y metodo para su uso. Download PDFInfo
- Publication number
- ES2293977T3 ES2293977T3 ES01908880T ES01908880T ES2293977T3 ES 2293977 T3 ES2293977 T3 ES 2293977T3 ES 01908880 T ES01908880 T ES 01908880T ES 01908880 T ES01908880 T ES 01908880T ES 2293977 T3 ES2293977 T3 ES 2293977T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- antiviral
- peptide
- seq
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 179
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 124
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 73
- 238000000034 method Methods 0.000 title description 19
- 241000700605 Viruses Species 0.000 claims abstract description 68
- 230000009385 viral infection Effects 0.000 claims abstract description 13
- 208000036142 Viral infection Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 241000700584 Simplexvirus Species 0.000 claims description 26
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 230000003612 virological effect Effects 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 239000012528 membrane Substances 0.000 abstract description 24
- 239000012634 fragment Substances 0.000 abstract description 4
- 244000309711 non-enveloped viruses Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 50
- 238000010276 construction Methods 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 230000007704 transition Effects 0.000 description 15
- 210000003501 vero cell Anatomy 0.000 description 15
- 210000002845 virion Anatomy 0.000 description 15
- 239000003443 antiviral agent Substances 0.000 description 14
- 101150066555 lacZ gene Proteins 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 9
- 229960004150 aciclovir Drugs 0.000 description 9
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 229940121357 antivirals Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 5
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 3
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 101800000342 Glycoprotein C Proteins 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- RVEVENLSADZUMS-IHRRRGAJSA-N Phe-Pro-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RVEVENLSADZUMS-IHRRRGAJSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 101150048066 UL45 gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003253 viricidal effect Effects 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- GFWLIJDQILOEPP-HSCHXYMDSA-N Lys-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N GFWLIJDQILOEPP-HSCHXYMDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 101150093191 RIR1 gene Proteins 0.000 description 2
- 108010090851 Simplexvirus DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UUIYFDAWNBSWPG-IHPCNDPISA-N Trp-Lys-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N UUIYFDAWNBSWPG-IHPCNDPISA-N 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VWWKKDNCCLAGRM-GVXVVHGQSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VWWKKDNCCLAGRM-GVXVVHGQSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- UAXIKORUDGGIGA-DCAQKATOSA-N Asp-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O UAXIKORUDGGIGA-DCAQKATOSA-N 0.000 description 1
- 101710195313 Beta-galactosidase 8 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710160937 DNA replication protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- LXXLEUBUOMCAMR-NKWVEPMBSA-N Gly-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)CN)C(=O)O LXXLEUBUOMCAMR-NKWVEPMBSA-N 0.000 description 1
- UMBDRSMLCUYIRI-DVJZZOLTSA-N Gly-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O UMBDRSMLCUYIRI-DVJZZOLTSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000037195 Herpes simplex virus stromal keratitis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 description 1
- 241000700326 Human herpesvirus 1 strain KOS Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- FZIJIFCXUCZHOL-CIUDSAMLSA-N Lys-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN FZIJIFCXUCZHOL-CIUDSAMLSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- KYNNSEJZFVCDIV-ZPFDUUQYSA-N Lys-Ile-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O KYNNSEJZFVCDIV-ZPFDUUQYSA-N 0.000 description 1
- KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000005956 cytoplasmic translocation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003503 early effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010009932 leucyl-alanyl-glycyl-valine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18082300P | 2000-02-07 | 2000-02-07 | |
| US180823P | 2000-02-07 | ||
| US18405700P | 2000-02-22 | 2000-02-22 | |
| US184057P | 2000-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2293977T3 true ES2293977T3 (es) | 2008-04-01 |
Family
ID=26876670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01908880T Expired - Lifetime ES2293977T3 (es) | 2000-02-07 | 2001-02-06 | Peptidos antivirales farmacologicamente activos y metodo para su uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7371809B2 (enExample) |
| EP (1) | EP1272510B1 (enExample) |
| JP (1) | JP4896333B2 (enExample) |
| AT (1) | ATE374208T1 (enExample) |
| AU (1) | AU784264B2 (enExample) |
| CA (1) | CA2399676C (enExample) |
| DE (1) | DE60130641T2 (enExample) |
| ES (1) | ES2293977T3 (enExample) |
| WO (1) | WO2001057072A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1272510B1 (en) | 2000-02-07 | 2007-09-26 | Wisconsin Alumni Research Foundation | Pharmacologically active antiviral peptides and methods of their use |
| US7094413B2 (en) * | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
| US7432045B2 (en) | 2003-12-01 | 2008-10-07 | Wisconsin Alumni Research Foundation | Method of inhibiting influenza infection with antiviral peptides |
| JP4831410B2 (ja) | 2006-02-28 | 2011-12-07 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよび抗ウイルス剤 |
| CA2727898A1 (en) | 2008-06-13 | 2009-12-17 | Wisconsin Alumni Research Foundation | Novel antiviral peptides against influenza virus |
| WO2009152518A1 (en) * | 2008-06-13 | 2009-12-17 | Wisconsin Alumni Research Foundation | Novel peptide adjuvant for influenza vaccination |
| AU2009292959B2 (en) * | 2008-09-19 | 2016-02-25 | Henry Ford Health System | Methods, systems, and compositions for calpain inhibition |
| GB201012651D0 (en) * | 2010-07-28 | 2010-09-15 | Univ Edinburgh | Peptides |
| WO2012071549A2 (en) | 2010-11-24 | 2012-05-31 | Clontech Laboratories, Inc. | Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same |
| US20120190107A1 (en) * | 2011-01-26 | 2012-07-26 | Dwayne Bisgrove | Enhanced protein transduction |
| ES2444299B1 (es) | 2012-08-23 | 2014-12-12 | Nutrición Técnica Deportiva, S.L. | Uso de un hidrolizado de caseina como agente antiherpético |
| KR20200012894A (ko) | 2017-05-26 | 2020-02-05 | 비라매틱스 에스디엔 비에이치디 | 펩타이드 및 항바이러스제로서의 이의 용도 |
| KR20240067073A (ko) * | 2021-08-23 | 2024-05-16 | 아미트렉스 테라퓨틱스, 인크. | 백혈구 특이적 세포 투과 분자 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4795740A (en) * | 1986-05-20 | 1989-01-03 | Cohen Eric A | Antiviral peptides and means for treating herpes infections |
| US4814432A (en) | 1987-05-22 | 1989-03-21 | Merck & Co., Inc. | Inhibitor of ribonucleotide reductase |
| US5260420A (en) * | 1987-07-30 | 1993-11-09 | Centre Regional De Transfusion Sanguine De Lille | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof |
| US5104854A (en) * | 1989-02-01 | 1992-04-14 | Washington University | Antiviral peptides |
| CA1340682C (en) * | 1989-07-07 | 1999-07-27 | Pierre Lavallee | Antiviral peptides having a 2-oxoalkyl amino acid side chain |
| IT1231342B (it) * | 1989-08-28 | 1991-11-28 | Prodotti Antibiotici Spa | Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono |
| JPH0421635A (ja) | 1990-05-16 | 1992-01-24 | Suntory Ltd | アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物 |
| CA2033447C (en) * | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
| EP0531080A3 (en) | 1991-09-04 | 1993-12-29 | Merck & Co Inc | Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein |
| EP0726749B1 (en) * | 1993-11-03 | 2004-08-11 | Clarion Pharmaceuticals, Inc. | Hemostatic patch |
| US5441936A (en) * | 1993-12-07 | 1995-08-15 | Houghten Pharmaceuticals, Inc. | Antiviral peptides |
| US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| FR2739621B1 (fr) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| AU3982497A (en) | 1996-07-30 | 1998-02-20 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner |
| US5877282A (en) * | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| AU6972798A (en) * | 1997-04-18 | 1998-11-13 | University Of Medicine And Dentistry Of New Jersey | Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog |
| WO1999005302A1 (en) * | 1997-07-24 | 1999-02-04 | The Perkin-Elmer Corporation | Conjugates of transporter peptides and nucleic acid analogs, and their use |
| FR2766826B1 (fr) * | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
| WO1999064449A2 (en) * | 1998-06-10 | 1999-12-16 | The Queen's University Of Belfast | Cell-permeable peptide |
| EP1272510B1 (en) | 2000-02-07 | 2007-09-26 | Wisconsin Alumni Research Foundation | Pharmacologically active antiviral peptides and methods of their use |
| US7432045B2 (en) | 2003-12-01 | 2008-10-07 | Wisconsin Alumni Research Foundation | Method of inhibiting influenza infection with antiviral peptides |
-
2001
- 2001-02-06 EP EP01908880A patent/EP1272510B1/en not_active Expired - Lifetime
- 2001-02-06 AU AU36700/01A patent/AU784264B2/en not_active Ceased
- 2001-02-06 CA CA2399676A patent/CA2399676C/en not_active Expired - Fee Related
- 2001-02-06 WO PCT/US2001/003813 patent/WO2001057072A2/en not_active Ceased
- 2001-02-06 US US09/777,560 patent/US7371809B2/en not_active Expired - Fee Related
- 2001-02-06 DE DE60130641T patent/DE60130641T2/de not_active Expired - Lifetime
- 2001-02-06 ES ES01908880T patent/ES2293977T3/es not_active Expired - Lifetime
- 2001-02-06 AT AT01908880T patent/ATE374208T1/de not_active IP Right Cessation
- 2001-02-06 JP JP2001557903A patent/JP4896333B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-02 US US12/061,378 patent/US8748565B2/en not_active Expired - Fee Related
- 2008-11-07 US US12/291,325 patent/US8748566B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001057072A3 (en) | 2002-10-31 |
| AU3670001A (en) | 2001-08-14 |
| CA2399676C (en) | 2010-04-06 |
| US20120157376A1 (en) | 2012-06-21 |
| US8748565B2 (en) | 2014-06-10 |
| US7371809B2 (en) | 2008-05-13 |
| DE60130641D1 (de) | 2007-11-08 |
| US20090253624A1 (en) | 2009-10-08 |
| EP1272510A2 (en) | 2003-01-08 |
| EP1272510B1 (en) | 2007-09-26 |
| DE60130641T2 (de) | 2008-06-26 |
| AU784264B2 (en) | 2006-03-02 |
| ATE374208T1 (de) | 2007-10-15 |
| US8748566B2 (en) | 2014-06-10 |
| WO2001057072A2 (en) | 2001-08-09 |
| JP4896333B2 (ja) | 2012-03-14 |
| JP2003522185A (ja) | 2003-07-22 |
| CA2399676A1 (en) | 2001-08-09 |
| US20050130884A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8748565B2 (en) | Pharmacologically active antiviral peptides and methods of their use | |
| Heldwein et al. | Entry of herpesviruses into mammalian cells | |
| Schwartz et al. | Peptide-mediated cellular delivery. | |
| Heitz et al. | Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics | |
| Bultmann et al. | Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1 | |
| CN101415723A (zh) | 具有改良生物学特性的hiv融合抑制肽 | |
| USRE47838E1 (en) | Inhibitory peptides of viral infection | |
| Galdiero et al. | Intracellular delivery: exploiting viral membranotropic peptides | |
| Akkarawongsa et al. | Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry | |
| JP2020536582A (ja) | 遺伝子発現抑制剤 | |
| US7432045B2 (en) | Method of inhibiting influenza infection with antiviral peptides | |
| ES2338350T3 (es) | Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices. | |
| KR20220139079A (ko) | 세포 투과성 펩타이드 변이체 및 이의 용도 | |
| US10745448B2 (en) | Antiviral peptide and use therefor | |
| AU2006202024B2 (en) | Pharmacologically active antiviral peptides and methods of their use | |
| EP1862471A2 (en) | Pharmacologically active antiviral peptides and methods of their use | |
| WO2009152519A2 (en) | Novel antiviral peptides against influenza virus | |
| US8138146B2 (en) | Antiviral peptide and antiviral agent | |
| JP7333538B2 (ja) | 抗ウイルス性ペプチドおよびその利用 | |
| US11767345B2 (en) | Antiviral peptide and use thereof | |
| CN107485716B (zh) | 可运载功能性分子进入hsv可感染细胞的载体及药物 | |
| Heldweina et al. | Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111 (USA), Fax:+ 1 617 636 0337, e-mail: katya. heldwein@ tufts. edu b Department of Biochemistry, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania 19104 (USA) | |
| Beerens | Intercellular spread of the transgene product to improve the efficiency of cancer gene therapy |